Valeant's meltdown claims another top exec, this time at shareholder Sequoia

Sequoia Fund chief Robert Goldfarb bowed out of his post Wednesday after his big bet on Valeant Pharmaceuticals ($VRX) turned up sour. One of the embattled drugmaker's biggest shareholders, Sequoia at one point had 30% of its capital tied up in Valeant, MarketWatch reports. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.